227 related articles for article (PubMed ID: 37255232)
1. Daily associations with cannabis use and sleep quality in anxious cannabis users.
Bidwell LC; Sznitman SR; Martin-Willett R; Hitchcock LH
Behav Sleep Med; 2024 Mar; 22(2):150-167. PubMed ID: 37255232
[TBL] [Abstract][Full Text] [Related]
2. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
[TBL] [Abstract][Full Text] [Related]
3. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].
Morgan CJ; Schafer G; Freeman TP; Curran HV
Br J Psychiatry; 2010 Oct; 197(4):285-90. PubMed ID: 20884951
[TBL] [Abstract][Full Text] [Related]
4. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.
Bidwell LC; Karoly HC; Torres MO; Master A; Bryan AD; Hutchison KE
Psychopharmacology (Berl); 2022 Feb; 239(2):385-397. PubMed ID: 34708254
[TBL] [Abstract][Full Text] [Related]
5. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?
Freeman TP; Morgan CJ; Hindocha C; Schafer G; Das RK; Curran HV
Addiction; 2014 Oct; 109(10):1686-94. PubMed ID: 24894801
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
7. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV
J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
9. Baseline affective symptomatology moderates acute subjective effects of high potency THC and CBD cannabis concentrates.
Martin-Willett R; Skrzynski CJ; Karoly HC; Elmore JS; Bidwell LC
Exp Clin Psychopharmacol; 2023 Dec; 31(6):1039-1049. PubMed ID: 37289543
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Morgan CJ; Freeman TP; Schafer GL; Curran HV
Neuropsychopharmacology; 2010 Aug; 35(9):1879-85. PubMed ID: 20428110
[TBL] [Abstract][Full Text] [Related]
11. Effects of cannabidiol in cannabis flower: Implications for harm reduction.
Gibson LP; Karoly HC; Ellingson JM; Klawitter J; Sempio C; Squeri JE; Bryan AD; Bidwell LC; Hutchison KE
Addict Biol; 2022 Jan; 27(1):e13092. PubMed ID: 34467598
[TBL] [Abstract][Full Text] [Related]
12. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in the composition of marijuana seized in California.
Burgdorf JR; Kilmer B; Pacula RL
Drug Alcohol Depend; 2011 Aug; 117(1):59-61. PubMed ID: 21288662
[TBL] [Abstract][Full Text] [Related]
14. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
15. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
16. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Hammond D; Goodman S
Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
[No Abstract] [Full Text] [Related]
17. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
18. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.
Lawn W; Freeman TP; Pope RA; Joye A; Harvey L; Hindocha C; Mokrysz C; Moss A; Wall MB; Bloomfield MA; Das RK; Morgan CJ; Nutt DJ; Curran HV
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3537-52. PubMed ID: 27585792
[TBL] [Abstract][Full Text] [Related]
19. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
[TBL] [Abstract][Full Text] [Related]
20. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
